Central regions | Technology & innovation

Solution to treat advanced-stage cancers under way in Russia

9 Feb '17
TheraMAB, a Russian biotech company, has launched a new phase of clinical trials for its drug candidate, designated TAB08, to treat cancers at advanced stages, reported the website of RVC, Russia’s fund of funds for innovation. RVC has a shareholding in the biotech developer through Bioprocess Capital Ventures, a VC fund co-owned by RVC.

The new phase is expected to reveal the human body’s tolerance to the drug candidate and help assess possible immune response in an oncology patient.

The drug candidate is believed to be unique for its ability to address the very root of an oncologic disease by normalizing the functional balance between various types of immune cells—a drastic departure from conventional approach, in which drugs only deal with symptoms at later stages. The TAB08 drug candidate belongs to the IgG4 class of humanized monoclonal antibodies capable of binding the co-stimulating CB28 receptor specific for human T cells.

The candidate is reported to have already passed the initial clinical trial stage “with success” and proven its safety and good tolerance in healthy volunteers and autoimmune patients.

“We believe therapy using stimulating drugs in combination with molecules that can trigger or suppress the immune system will benefit future cancer patients to a great extent,” TheraMAB CEO Dmitry Tyrsin said.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content


Latest News: Central regions
22 Feb '17 | Telecoms, media | Industry, manufacturing
21 Feb '17 | Finance, business | Technology & innovation
15 Feb '17 | Technology & innovation
14 Feb '17 | Technology & innovation

Feature stories

25 Jan '17
ScreenCardio-NN, an innovative company based in...
7 Dec '16
In spite of all current problems and adverse external...
2 Nov '16
Search (News archive - 21039)
Nano & Giga Symposium
Report: Russian universities should modernize to compete globally
ITMO University

Latest News

22 Feb '17
Optic Fiber Systems, a Russian company, is ready to...
21 Feb '17
Russia’s leading universities may expect to receive...
20 Feb '17
A material almost identical to the human skin has...

Most read stories from last week

21 Feb '17
Russia’s leading universities may expect to receive...
22 Feb '17
Optic Fiber Systems, a Russian company, is ready to...